Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

CARIPRAZINE vs CASIRIVIMAB\IMDEVIMAB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

CARIPRAZINE vs CASIRIVIMAB\IMDEVIMAB: Safety Overview

Metric CARIPRAZINE CASIRIVIMAB\IMDEVIMAB
Total FAERS Reports 6,547 4,248
Deaths Reported 194 137
Death Rate 3.0% 3.2%
Hospitalizations 702 1,351
Average Patient Age 40.4 yrs 54.3 yrs
% Female Patients 64.0% 55.4%
FDA Approval Date Dec 16, 2025 N/A
Manufacturer Allergan, Inc. N/A
Route ORAL N/A
Marketing Status Prescription N/A